Trial Profile
A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE-DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF CIM331 IN ATOPIC DERMATITIS PATIENTS WHO ARE INADEQUATELY CONTROLLED BY OR INTOLERANT TO TOPICAL THERAPY
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Jan 2022
Price :
$35
*
At a glance
- Drugs Nemolizumab (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Acronyms XCIMA
- Sponsors Chugai Pharmaceutical
- 09 Jun 2018 According to the results of a 52-week double-blind extension (Part B) published in the Journal of Allergy and Clinical Immunology, the database was unblinded on 9 Sep 2016 for analysis of Part B.
- 09 May 2018 Results of a 52-week double-blind extension (Part B), published in the Journal of Allergy and Clinical Immunology.
- 13 Jul 2017 Results of population pharmacokinetic analysis from two studies including this study published in the Journal of Clinical Pharmacology